Toll-like receptor 3 signaling via TRIF contributes to a protective innate immune response to severe acute respiratory syndrome coronavirus infection

mBio

Volumn 6, Issue 3, 2015, Pages 1-14

  Totura, Allison L ^a   Whitmore, Alan ^a   Agnihothram, Sudhakar ^b,d   Schäfer, Alexandra ^b   Katze, Michael G ^c   Heise, Mark T ^a   Baric, Ralph S ^a,b  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b IL   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d National Center for Toxicological Research   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERLEUKIN 6; MYELOID DIFFERENTIATION FACTOR 88; RANTES; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR ADAPTOR MOLECULE 1; TOLL LIKE RECEPTOR ADAPTOR MOLECULE 2; TUMOR NECROSIS FACTOR; INTERLEUKIN RECEPTOR; TICAM-1 PROTEIN, MOUSE; TIRP PROTEIN, MOUSE; TLR3 PROTEIN, MOUSE; TLR4 PROTEIN, MOUSE; VESICULAR TRANSPORT ADAPTOR PROTEIN;

ADULT RESPIRATORY DISTRESS SYNDROME; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; INFECTION SENSITIVITY; INFLAMMATORY CELL; INFLUENZA VIRUS; INNATE IMMUNITY; LUNG DISEASE; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS; MORTALITY; MOUSE; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN DEFICIENCY; PROTEIN EXPRESSION; SARS CORONAVIRUS; SEVERE ACUTE RESPIRATORY SYNDROME; SIGNAL TRANSDUCTION; VIRUS VIRULENCE; WEIGHT REDUCTION; WILD TYPE; ANIMAL; BODY WEIGHT; DEFICIENCY; DISEASE PREDISPOSITION; IMMUNOLOGY; KNOCKOUT MOUSE; LUNG; LUNG FUNCTION TEST; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; SURVIVAL ANALYSIS; VIRUS LOAD;

CORONAVIRUS; FUNGI; MUS; ORTHOMYXOVIRIDAE; SARS CORONAVIRUS;

ADAPTOR PROTEINS, VESICULAR TRANSPORT; ANIMALS; BODY WEIGHT; DISEASE SUSCEPTIBILITY; IMMUNITY, INNATE; LUNG; MICE, KNOCKOUT; RECEPTORS, INTERLEUKIN; RESPIRATORY FUNCTION TESTS; SARS VIRUS; SIGNAL TRANSDUCTION; SURVIVAL ANALYSIS; TOLL-LIKE RECEPTOR 3; TOLL-LIKE RECEPTOR 4; VIRAL LOAD;

EID: 85013715067     PISSN: 21612129     EISSN: 21507511     Source Type: Journal    
DOI: 10.1128/mBio.00638-15     Document Type: Article

References (64)

1. Drosten C, Günther S, Preiser W, van der Werf S, Brodt H-R, Becker S, Rabenau H, Panning M, Kolesnikova L, Fouchier RA, Berger A, Burguière A-M, Cinatl J, Eickmann M, Escriou N, Grywna K, Kramme S, Manuguerra J-C, Müller S, Rickerts V, Stürmer M, Vieth S, Klenk H-D, Osterhaus ADME, Schmitz H, Doerr HW. 2003. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N Engl J Med 348:1967-1976. http://dx.doi.org/10.1056/NEJMoa030747.
2. Zaki AM, van Boheemen S, Bestebroer TM, Osterhaus AD, Fouchier RA. 2012. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med 367:1814-1820. http://dx.doi.org/10.1056/ NEJMoa1211721.
3. Stevenson GW, Hoang H, Schwartz KJ, Burrough ER, Sun D, Madson D, Cooper VL, Pillatzki A, Gauger P, Schmitt BJ, Koster LG, Killian ML, Yoon KJ. 2013. Emergence of porcine epidemic diarrhea virus in the United States: clinical signs, lesions, and viral genomic sequences. J Vet Diagn Invest 25:649-654. http://dx.doi.org/10.1177/1040638713501675.
4. WHO. 31 December 2003, posting date. Summary of probable SARS cases with onset of illness from 1 November 2002 to 31 July 2003. WHO, Geneva, Switzerland. http://www.who.int/csr/sars/country/ table2004_04_21/en/.
5. Ohnmeiss DD. 2015. ECDC Communicable Disease Threats Report (CDTR). European Center for Disease Control.
6. Anthony SJ, Epstein JH, Murray KA, Navarrete-Macias I, Zambrana-Torrelio CM, Solovyov A, Ojeda-Flores R, Arrigo NC, Islam A, Ali Khan S, Hosseini P, Bogich TL, Olival KJ, Sanchez-Leon MD, Karesh WB, Goldstein T, Luby SP, Morse SS, Mazet JAK, Daszak P, Lipkin WI. 2013. A strategy to estimate unknown viral diversity in mammals. mBio 4:e00598-13. http://dx.doi.org/10.1128/mBio.00598-13.
7. Al-Tawfiq JA, Momattin H, Dib J, Memish ZA. 2014. Ribavirin and interferon therapy in patients infected with the Middle East respiratory syndrome coronavirus: an observational study. Int J Infect Dis 20:42-46. http://dx.doi.org/10.1016/j.ijid.2013.12.003.
8. Stockman LJ, Bellamy R, Garner P. 2006. SARS: systematic review of treatment effects. PLoS Med 3:e343. http://dx.doi.org/10.1371/ journal.pmed.0030343.
9. Falzarano D, de Wit E, Martellaro C, Callison J, Munster VJ, Feldmann H. 2013. Inhibition of novelβ coronavirus replication by a combination of interferon-α2b and ribavirin. Sci Rep 3:1686. http://dx.doi.org/10.1038/ srep01686.
10. Ge X-Y, Li J-L, Yang X-L, Chmura AA, Zhu G, Epstein JH, Mazet JK, Hu B, Zhang W, Peng C, Zhang Y-J, Luo C-M, Tan B, Wang N, Zhu Y, Crameri G, Zhang S-Y, Wang L-F, Daszak P, Shi Z-L. 2013. Isolation and characterization of a bat SARS-like coronavirus that uses the ACE2 receptor. Nature 503:535-538. http://dx.doi.org/10.1038/nature12711.
11. Bolles M, Deming D, Long K, Agnihothram S, Whitmore A, Ferris M, Funkhouser W, Gralinski L, Totura A, Heise M, Baric RS. 2011. A double-inactivated severe acute respiratory syndrome coronavirus vaccine provides incomplete protection in mice and induces increased eosinophilic proinflammatory pulmonary response upon challenge. J Virol 85: 12201-12215. http://dx.doi.org/10.1128/JVI.06048-11.
12. Deming D, Sheahan T, Heise M, Yount B, Davis N, Sims A, Suthar M, Harkema J, Whitmore A, Pickles R, West A, Donaldson E, Curtis K, Johnston R, Baric R. 2006. Vaccine efficacy in senescent mice challenged with recombinant SARS-CoV bearing epidemic and zoonotic spike variants. PLoS Med 3:e525. http://dx.doi.org/10.1371/journal.pmed.0030525.
13. Short KR, Kroeze EJ, Fouchier RA, Kuiken T. 2014. Pathogenesis of influenza-induced acute respiratory distress syndrome. Lancet Infect Dis 14:57-69. http://dx.doi.org/10.1016/S1473-3099(13)70286-X.
14. Chow K, Hsiao C, Lin T, Chen C, Chiou S. 2004. Detection of severe acute respiratory syndrome associated coronavirus in pneumocytes of the lung. Am J Clin Pathol 121:574-580. http://dx.doi.org/10.1309/ C0EDU0RAQBTXBHCE.
15. Yoo J-K, Kim TS, Hufford MM, Braciale TJ. 2013. Viral infection of the lung: host response and sequelae. J Allergy Clin Immunol 132:1263-1276. http://dx.doi.org/10.1016/j.jaci.2013.06.006.
16. Le Goffic R, Balloy V, Lagranderie M, Alexopoulou L, Escriou N, Flavell R, Chignard M, Si-Tahar M. 2006. Detrimental contribution of the Tolllike receptor (TLR)3 to influenza A virus-induced acute pneumonia. PLoS Pathog 2:e53. http://dx.doi.org/10.1371/journal.ppat.0020053.
17. Rudd BD, Smit JJ, Flavell RA, Alexopoulou L, Schaller MA, Gruber A, Berlin AA, Lukacs NW. 2006. Deletion of TLR3 alters the pulmonary immune environment and mucus production during respiratory syncytial virus infection. J Immunol 176:1937-1942. http://dx.doi.org/10.4049/ jimmunol.176.3.1937.
18. Wang Q, Miller DJ, Bowman ER, Nagarkar DR, Schneider D, Zhao Y, Linn MJ, Goldsmith AM, Bentley JK, Sajjan US, Hershenson MB. 2011. MDA5 and TLR3 initiate pro-inflammatory signaling pathways leading to rhinovirus-induced airways inflammation and hyperresponsiveness. PLoS P a t h o g 7 : e 1 0 0 2 0 7 0 . h t t p : / / d x . d o i . o r g / 1 0 . 1 3 7 1 / journal.ppat.1002070.
19. Guillot L, Le Goffic R, Bloch S, Escriou N, Akira S, Chignard M, Si-Tahar M. 2005. Involvement of Toll-like receptor 3 in the immune response of lung epithelial cells to double-stranded RNA and influenza A virus. J Biol Chem 280:5571-5580. http://dx.doi.org/10.1074/ jbc.M410592200.
20. Alexopoulou L, Holt AC, Medzhitov R, Flavell RA. 2001. Recognition of double-stranded RNA and activation of NF-[kappa]B by Toll-like receptor 3. Nature 413:732-738. http://dx.doi.org/10.1038/35099560.
21. Oshiumi H, Matsumoto M, Funami K, Akazawa T, Seya T. 2003. TICAM-1, an adaptor molecule that participates in Toll-like receptor 3-mediated interferon-[beta] induction. Nat Immunol 4:161-167. http:// dx.doi.org/10.1038/ni886.
22. Yamamoto M, Sato S, Hemmi H, Hoshino K, Kaisho T, Sanjo H, Takeuchi O, Sugiyama M, Okabe M, Takeda K, Akira S. 2003. Role of adaptor TRIF in the MyD88-independent Toll-like receptor signaling pathway. Science 301:640-643. http://dx.doi.org/10.1126/ science.1087262.
23. Yamamoto M, Sato S, Mori K, Hoshino K, Takeuchi O, Takeda K, Akira S. 2002. Cutting edge: a novel Toll/IL-1 receptor domaincontaining adapter that preferentially activates the IFN-β promoter in the Toll-like receptor signaling. J Immunol 169:6668-6672. http:// dx.doi.org/10.4049/jimmunol.169.12.6668.
24. Zhang Z, Kim T, Bao M, Facchinetti V, Jung SY, Ghaffari AA, Qin J, Cheng G, Liu Y-J. 2011. DDX1, DDX21, and DHX36 helicases form a complex with the adaptor molecule TRIF to sense dsRNA in dendritic c e l l s . Immunity 34:866-878. http://dx.doi.org/10.1016/ j.immuni.2011.03.027.
25. Guillot L, Medjane S, Le-Barillec K, Balloy V, Danel C, Chignard M, Si-TaharM. 2004. Response of human pulmonary epithelial cells to lipopolysaccharide involves Toll-like receptor 4 (TLR4)-dependent signaling pathways: evidence for an intracellular compartmentalization of TLR4. J Biol Chem 279:2712-2718. http://dx.doi.org/10.1074/jbc.M305790200.
26. Monick MM, Yarovinsky TO, Powers LS, Butler NS, Carter AB, Gudmundsson G, Hunninghake GW. 2003. Respiratory syncytial virus upregulates TLR4 and sensitizes airway epithelial cells to endotoxin. J Biol Chem 278:53035-53044. http://dx.doi.org/10.1074/jbc.M308093200.
27. O'Neill LA, Bowie AG. 2007. The family of five: TIR-domain-containing adaptors in Toll-like receptor signalling. Nat Rev Immunol 7:353-364. http://dx.doi.org/10.1038/nri2079.
28. Imai Y, Kuba K, Neely GG, Yaghubian-Malhami R, Perkmann T, van Loo G, Ermolaeva M, Veldhuizen R, Leung YH, Wang H, Liu H, Sun Y, Pasparakis M, Kopf M, Mech C, Bavari S, Peiris JS, Slutsky AS, Akira S, Hultqvist M, Holmdahl R, Nicholls J, Jiang C, Binder CJ, Penninger JM. 2008. Identification of oxidative stress and Toll-like receptor 4 signaling as a key pathway of acute lung injury. Cell 133:235-249. http:// dx.doi.org/10.1016/j.cell.2008.02.043.
29. Shirey KA, Lai W, Scott AJ, Lipsky M, Mistry P, Pletneva LM, Karp CL, McAlees J, Gioannini TL, Weiss J, Chen WH, Ernst RK, Rossignol DP, Gusovsky F, Blanco JC, Vogel SN. 2013. The TLR4 antagonist Eritoran protects mice from lethal influenza infection. Nature 497:498-502. http:// dx.doi.org/10.1038/nature12118.
30. Morales-Nebreda L, Mutlu GM, Scott Budinger GR, Radigan KA. 2014. Loss of TLR4 does not prevent influenza A-induced mortality.AmJ Respir Crit Care Med 189:1280-1281. http://dx.doi.org/10.1164/rccm.201401-0193LE.
31. Khanolkar A, Hartwig SM, Haag BA, Meyerholz DK, Harty JT, Varga SM. 2009. Toll-like receptor 4 deficiency increases disease and mortality after mouse hepatitis virus type 1 infection of susceptible C3H mice. J Virol 83:8946-8956. http://dx.doi.org/10.1128/JVI.01857-08.
32. Ichikawa A, Kuba K, Morita M, Chida S, Tezuka H, Hara H, Sasaki T, Ohteki T, Ranieri VM, dos Santos CC, Kawaoka Y, Akira S, Luster AD, Lu B, Penninger JM, Uhlig S, Slutsky AS, Imai Y. 2013. CXCL10-CXCR3 enhances the development of neutrophil-mediated fulminant lung injury of viral and nonviral origin. Am J Respir Crit Care Med 187:65-77. http:// dx.doi.org/10.1164/rccm.201203-0508OC.
33. Zhao J, Wohlford-Lenane C, Zhao J, Fleming E, Lane TE, McCray PB, Perlman S. 2012. Intranasal treatment with poly(I·C) protects aged mice from lethal respiratory virus infections. J Virol 86:11416-11424. http:// dx.doi.org/10.1128/JVI.01410-12.
34. Iwata-Yoshikawa N, Uda A, Suzuki T, Tsunetsugu-Yokota Y, Sato Y, Morikawa S, Tashiro M, Sata T, Hasegawa H, Nagata N. 2014. Effects of Toll-like receptor stimulation on eosinophilic infiltration in lungs of BALB/c mice immunized with UV-inactivated severe acute respiratory syndrome-related coronavirus vaccine. J Virol 88:8597-8614. http:// dx.doi.org/10.1128/JVI.00983-14.
35. Pérez-Girón JV, Belicha-Villanueva A, Hassan E, Gómez-Medina S, Cruz JL, Lüdtke A, Ruibal P, Albrecht RA, García-Sastre A, Muñoz-Fontela C. 2014. Mucosal polyinosinic-polycytidylic acid improves protection elicited by replicating influenza vaccines via enhanced dendritic cell function and T cell immunity. J Immunol 193:1324-1332. http:// dx.doi.org/10.4049/jimmunol.1400222.
36. Zhao J, Li K, Wohlford-Lenane C, Agnihothram SS, Fett C, Zhao J, Gale MJ, Baric RS, Enjuanes L, Gallagher T, McCray PB, Perlman S. 2014. Rapid generation of a mouse model for Middle East respiratory syndrome. Proc Natl Acad Sci U S A 111:4970-4975. http://dx.doi.org/10.1073/ pnas.1323279111.
37. Sheahan T, Morrison TE, Funkhouser W, Uematsu S, Akira S, Baric RS, Heise MT. 2008. MyD88 is required for protection from lethal infection with a mouse-adapted SARS-CoV. PLoS Pathog 4:e1000240. http:// dx.doi.org/10.1371/journal.ppat.1000240.
38. Gralinski LE, Bankhead A, Jeng S, Menachery VD, Proll S, Belisle SE, Matzke M, Webb-Robertson BJ, Luna ML, Shukla AK, Ferris MT, Bolles M, Chang J, Aicher L, Waters KM, Smith RD, Metz TO, Law GL, Katze MG, McWeeney S, Baric RS. 2013. Mechanisms of severe acute respiratory syndrome coronavirus-induced acute lung injury. mBio 4:e00271-13. http://dx.doi.org/10.1128/mBio.00271-13.
39. Mitchell HD, Eisfeld AJ, Sims AC, McDermott JE, Matzke MM, Webb-Robertson BJ, Tilton SC, Tchitchek N, Josset L, Li C, Ellis AL, Chang JH, Heegel RA, Luna ML, Schepmoes AA, Shukla AK, Metz TO, Neumann G, Benecke AG, Smith RD, Baric RS, Kawaoka Y, Katze MG, Waters KM. 2013. A network integration approach to predict conserved regulators related to pathogenicity of influenza and SARS-CoV respiratory viruses. PLoS One 8:e69374. http://dx.doi.org/10.1371/ journal.pone.0069374.
40. Hamelin ME, Prince GA, Gomez AM, Kinkead R, Boivin G. 2006. Human metapneumovirus infection induces long-term pulmonary inflammation associated with airway obstruction and hyperresponsiveness in mice. J Infect Dis 193:1634-1642. http://dx.doi.org/10.1086/504262.
41. Schwarze J, Hamelmann E, Bradley KL, Takeda K, Gelfand EW. 1997. Respiratory syncytial virus infection results in airway hyperresponsiveness and enhanced airway sensitization to allergen. J Clin Invest 100:226-233. http://dx.doi.org/10.1172/JCI119516.
42. Menachery VD, Yount BL, Josset L, Gralinski LE, Scobey T, Agnihothram S, Katze MG, Baric RS. 2014. Attenuation and restoration of severe acute respiratory syndrome coronavirus mutant lacking 2=-Omethyltransferase activity. J Virol 88:4251-4264. http://dx.doi.org/ 10.1128/JVI.03571-13.
43. Palmer LA, May WJ, deRonde K, Brown-Steinke K, Gaston B, Lewis SJ. 2013. Hypoxia-induced ventilatory responses in conscious mice: gender differences in ventilatory roll-off and facilitation. Respir Physiol Neurobiol 185:497-505. http://dx.doi.org/10.1016/j.resp.2012.11.010.
44. Cameron MJ, Ran L, Xu L, Danesh A, Bermejo-Martin JF, Cameron CM, Muller MP, Gold WL, Richardson SE, Poutanen SM, Willey BM, DeVries ME, Fang Y, Seneviratne C, Bosinger SE, Persad D, Wilkinson P, Greller LD, Somogyi R, Humar A, Keshavjee S, Louie M, Loeb MB, Brunton J, McGeer AJ; Canadian SARS Research Network, Kelvin DJ. 2007. Interferon-mediated immunopathological events are associated with atypical innate and adaptive immune responses in patients with severe acute respiratory syndrome. J Virol 81:8692-8706. http://dx.doi.org/ 10.1128/JVI.00527-07.
45. Faure E, Poissy J, Goffard A, Fournier C, Kipnis E, Titecat M, Bortolotti P, Martinez L, Dubucquoi S, Dessein R, Gosset P, Mathieu D, Guery B. 2014. Distinct immune response in two MERS-CoV-infected patients: can we go from bench to bedside? PLoS One 9:e88716. http://dx.doi.org/ 10.1371/journal.pone.0088716.
46. Menasria R, Boivin N, Lebel M, Piret J, Gosselin J, Boivin G. 2013. Both TRIF and IPS-1 adaptor proteins contribute to the cerebral innate immune response against herpes simplex virus 1 infection. J Virol 87: 7301-7308. http://dx.doi.org/10.1128/JVI.00591-13.
47. Seo S-U, Kwon H-J, Song J-H, Byun Y-H, Seong BL, Kawai T, Akira S, Kweon M-N. 2010. MyD88 signaling is indispensable for primary influenza A virus infection but dispensable for secondary infection. J Virol 84:12713-12722. http://dx.doi.org/10.1128/JVI.01675-10.
48. Menachery VD, Eisfeld AJ, Schäfer A, Josset L, Sims AC, Proll S, Fan S, Li C, Neumann G, Tilton SC, Chang J, Gralinski LE, Long C, Green R, Williams CM, Weiss J, Matzke MM, Webb-Robertson B-J, Schepmoes AA, Shukla AK, Metz TO, Smith RD, Waters KM, Katze MG, Kawaoka Y, Baric RS. 2014. Pathogenic influenza viruses and coronaviruses utilize similar and contrasting approaches to control interferon-stimulated gene responses. mBio 5:e01174-14. http://dx.doi.org/10.1128/mBio.01174-14.
49. Williams AE, Chambers RC. 2014. The mercurial nature of neutrophils: still an enigma in ARDS? Am J Physiol Lung Cell Mol Physiol 306: L217-L230. http://dx.doi.org/10.1152/ajplung.00311.2013.
50. Perrone LA, Plowden JK, García-Sastre A, Katz JM, Tumpey TM. 2008. H5N1 and 1918 pandemic influenza virus infection results in early and excessive infiltration of macrophages and neutrophils in the lungs of mice. PLoS P a t h o g 4 : e 1 0 0 0 1 1 5 . h t t p : / / d x . d o i . o r g / 1 0 . 1 3 7 1 / journal.ppat.1000115.
51. Seo S-U, Kwon H-J, Ko H-J, Byun Y-H, Seong BL, Uematsu S, Akira S, Kweon M-N. 2011. Type I interferon signaling regulates Ly6Chi monocytes and neutrophils during acute viral pneumonia in mice. PLoS Pathog 7:e1001304. http://dx.doi.org/10.1371/journal.ppat.1001304.
52. Shi C, Pamer EG. 2011. Monocyte recruitment during infection and inflammation. Nat Rev Immunol 11:762-774. http://dx.doi.org/10.1038/ nri3070.
53. Züst R, Cervantes-Barragan L, Habjan M, Maier R, Neuman BW, Ziebuhr J, Szretter KJ, Baker SC, Barchet W, Diamond MS, Siddell SG, Ludewig B, Thiel V. 2011. Ribose 2[prime]-O-methylation provides a molecular signature for the distinction of self and non-self mRNA dependent on the RNA sensor Mda5. Nat Immunol 12:137-143. http:// dx.doi.org/10.1038/ni.1979.
54. Frieman MB, Chen J, Morrison TE, Whitmore A, Funkhouser W, Ward JM, Lamirande EW, Roberts A, Heise M, Subbarao K, Baric RS. 2010. SARS-CoV pathogenesis is regulated by a STAT1 dependent but a type I, II and III interferon receptor independent mechanism. PLoS Pathog 6:e1000849. http://dx.doi.org/10.1371/journal.ppat.1000849.
55. Leung YH, Nicholls JM, Ho C-K, Sia S-F, Mok CK, Valkenburg SA, Cheung P, Hui KP, Chan RW, Guan Y, Akira S, Peiris JS. 2014. Highly pathogenic avian influenza A H5N1 and pandemic H1N1 virus infections have different phenotypes in Toll-like receptor (TLR) 3 knock-out mice. J Gen Virol 95:1870-1879. http://dx.doi.org/10.1099/vir.0.066258-0.
56. Daffis S, Samuel MA, Suthar MS, Gale M, Diamond MS. 2008. Toll-like receptor 3 has a protective role against West Nile virus infection. J Virol 82:10349-10358. http://dx.doi.org/10.1128/JVI.00935-08.
57. Wang T, Town T, Alexopoulou L, Anderson JF, Fikrig E, Flavell RA. 2004. Toll-like receptor 3 mediates West Nile virus entry into the brain causing lethal encephalitis. Nat Med 10:1366-1373. http://dx.doi.org/ 10.1038/nm1140.
58. Kumar H, Koyama S, Ishii KJ, Kawai T, Akira S. 2008. Cutting edge: cooperation of IPS-1-and TRIF-dependent pathways in poly ICenhanced antibody production and cytotoxic T cell responses. J Immunol 180:683-687. http://dx.doi.org/10.4049/jimmunol.180.2.683.
59. Mandraju R, Murray S, Forman J, Pasare C. 2014. Differential ability of surface and endosomal TLRs to induce CD8 T cell responses in vivo. J Immunol 192:4303-4315. http://dx.doi.org/10.4049/jimmunol.1302244.
60. Roberts A, Deming D, Paddock CD, Cheng A, Yount B, Vogel L, Herman BD, Sheahan T, Heise M, Genrich GL, Zaki SR, Baric R, Subbarao K. 2007. A mouse-adapted SARS-coronavirus causes disease and mortality in BALB/c mice. PLoS Pathog 3:e5. http://dx.doi.org/ 10.1371/journal.ppat.0030005.
61. Agnihothram S, Yount BL, Donaldson EF, Huynh J, Menachery VD, Gralinski LE, Graham RL, Becker MM, Tomar S, Scobey TD, Osswald HL, Whitmore A, Gopal R, Ghosh AK, Mesecar A, Zambon M, Heise M, Denison MR, Baric RS. 2014. A mouse model for betacoronavirus subgroup 2c using a bat coronavirus strain HKU5 variant. mBio 5:e00047-14. http://dx.doi.org/10.1128/mBio.00047-14.
62. Hamelmann E, Schwarze J, Takeda K, Oshiba A, Larsen GL, Irvin CG, GelfandEW. 1997. Noninvasive measurement of airway responsiveness in allergic mice using barometric plethysmography. Am J Respir Crit Care Med 156:766-775. http://dx.doi.org/10.1164/ajrccm.156.3.9606031.
63. Zhang Q, Lai K, Xie J, Chen G, Zhong N. 2009. Does unrestrained single-chamber plethysmography provide a valid assessment of airway responsiveness in allergic BALB/c mice? Respir Res 10:61. http:// dx.doi.org/10.1186/1465-9921-10-61.
64. Julander JG, Kesler K, Van Wettere AJ, Morrey JD, Smee DF. 2014. The use of plethysmography in determining the severity of lung pathology in a mouse model of minimally lethal influenza virus infection. Antiviral Res 108:10-13. http://dx.doi.org/10.1016/j.antiviral.2014.05.002.